Periostin expression in neoplastic and non-neoplastic diseases of bone and joint
ConclusionsIn keeping with its known role in modulating the synthesis of collagen and other extracellular matrix proteins in bone, strong periostin expression was noted in benign and malignant lesions forming an osteoid or osteoid-like matrix. Periostin was also noted in other bone tumours and was found in areas of reactive bone and increased vascularity at the edge of growing tumours, consistent with its involvement in tissue remodelling and angiogenesis associated with tumour progression. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - September 5, 2018 Category: Cancer & Oncology Source Type: research
Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis
ConclusionsKaryotyping and molecular genetic analysis may contribute to a conclusive diagnosis. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - August 23, 2018 Category: Cancer & Oncology Source Type: research
Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
This report summarizes the proceedings of the 4th European Bone Sarcoma Networking Meeting, held in London, England, on 21 June 2017. The meeting brought together scientific and clinical researchers and representatives from sarcoma charities from 19 countries representing five networks across Europe, to present and discuss new developments on bone sarcoma. In view of the challenges is poses, the meeting focussed primarily on osteosarcoma with presentations on developments in our understanding of osteosarcoma genetics and immunology as well as results from preclinical investigations and discussion of recent and ongoing clin...
Source: Clinical Sarcoma Research - August 10, 2018 Category: Cancer & Oncology Source Type: research
PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
AbstractNew treatment options for advanced osteosarcoma have remained limited. The platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) pathway plays an important role in the development and metastasis of osteosarcoma, via either direct autocrine stimulation of tumor cells, or paracrine stimulation on tumor stromal cells. It promotes angiogenesis to overcome hypoxia in the tumor microenvironment, and modulates tumor interstitial fluid pressure to control the influx and efflux of other agents. Targeting the PDGF/PDGFR pathway is a promising therapeutic method to overcome drug resistance and ...
Source: Clinical Sarcoma Research - August 2, 2018 Category: Cancer & Oncology Source Type: research
Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
ConclusionsThis case illustrates the effectiveness of systemic therapy in controlling a disease associated with high surgical morbidity. This approach may be especially useful in the treatment of extra-articular disease which often invades neurovascular bundles; as the effectiveness in metastatic disease is still unknown. In the future, systemic treatment for TGCT may be appropriate for the neoadjuvant setting to decrease disease burden prior to surgery with the aim of decreasing recurrence rates. However, properly designed prospective studies will need to be carried out to answer these questions. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 10, 2018 Category: Cancer & Oncology Source Type: research
Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts
ConclusionIn comparative cohorts, the outcomes of patients undergoing induction ILP prior to surgery did not differ from those undergoing standard management, although induction ILP was associated with a reduced need for adjuvant radiation. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 2, 2018 Category: Cancer & Oncology Source Type: research
Reversible rituximab-induced rectal Kaposi ’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma
ConclusionsTo our knowledge, this is the third case of Kaposi ’s sarcoma diagnosed under rituximab in a HIV-negative patient, the first one at the rectal level and the first one that completely regresses after stop of rituximab. This case raises awareness of iatrogenic Kaposi’s sarcoma in HIV-negative patients treated with rituximab, and further highlights the importance of immunosuppression in the pathophysiology of disease. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - June 11, 2018 Category: Cancer & Oncology Source Type: research
